Search   
MSDS  : Indol-4-ol, 3-(2-(dimethylamino)ethyl)-, dihydrogen phosphate
CAS  : 520-52-5
SYNONYMS  : * CY-39 * 3-(2-(Dimethylamino)ethyl)-1H-indol-4-ol dihydrogen phosphate ester * 3-2'-Dimethylaminoethylindol-4-phosphate * 3-(2-Dimethylaminoethyl)indol-4-yl dihydrogen phosphate * Indocybin * O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine * 4-Phosphoryloxy-omega-N,N-dimethyltryptamine * Psilocibin * Psilocin phosphate ester * Psilocybin * Psilotsibin * Psilocybine * Teonanacatl
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : NM3150000
CHEMICAL NAME : Indol-4-ol, 3-(2-(dimethylamino)ethyl)-, dihydrogen
phosphate
CAS REGISTRY NUMBER : 520-52-5
BEILSTEIN REFERENCE NO. : 0273158
REFERENCE : 4-22-00-05665 (Beilstein Handbook Reference)
LAST UPDATED : 199612
DATA ITEMS CITED : 12
MOLECULAR FORMULA : C12-H17-N2-O4-P
MOLECULAR WEIGHT : 284.28
WISWESSER LINE NOTATION : T56 BMJ D2N1&1 FOPQQO
COMPOUND DESCRIPTOR : Drug
Mutagen
Human
SYNONYMS/TRADE NAMES :
* CY-39
* 3-(2-(Dimethylamino)ethyl)-1H-indol-4-ol dihydrogen phosphate ester
* 3-2'-Dimethylaminoethylindol-4-phosphate
* 3-(2-Dimethylaminoethyl)indol-4-yl dihydrogen phosphate
* Indocybin
* O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine
* 4-Phosphoryloxy-omega-N,N-dimethyltryptamine
* Psilocibin
* Psilocin phosphate ester
* Psilocybin
* Psilotsibin
* Psilocybine
* Teonanacatl

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Human
DOSE/DURATION : 75 ug/kg
TOXIC EFFECTS :
Behavioral - euphoria
Behavioral - hallucinations, distorted perceptions
REFERENCE :
PSYPAG Psychopharmacologia (Berlin). (Berlin, Ger.) V.1-46, 1959-76. For
publisher information, see PSCHDL. Volume(issue)/page/year: 3,219,1962

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human
DOSE/DURATION : 60 ug/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - visual field changes
Behavioral - muscle weakness
Gastrointestinal - nausea or vomiting
REFERENCE :
JNMDAN Journal of Nervous and Mental Disease. (Williams & Wilkins Co., 428
E. Preston St., Baltimore, MD 21202) V.3- 1876- Volume(issue)/page/year:
131,428,1960

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Human
DOSE/DURATION : 37 ug/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - visual field changes
Behavioral - muscle weakness
Gastrointestinal - nausea or vomiting
REFERENCE :
JNMDAN Journal of Nervous and Mental Disease. (Williams & Wilkins Co., 428
E. Preston St., Baltimore, MD 21202) V.3- 1876- Volume(issue)/page/year:
131,428,1960

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Human
DOSE/DURATION : 130 ug/kg
TOXIC EFFECTS :
Behavioral - hallucinations, distorted perceptions
Behavioral - toxic psychosis
REFERENCE :
PSDTAP Proceedings of the European Society for the Study of Drug Toxicity.
(Princeton, NJ 08540) V.1-15, 1963-74. For publisher information, see
PESTD5. Volume(issue)/page/year: 8,59,1967

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 280 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and
D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,138,1972

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 420 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation)
Behavioral - convulsions or effect on seizure threshold
Gastrointestinal - changes in structure or function of salivary glands
REFERENCE :
NYKZAU Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. (Nippon
Yakuri Gakkai, c/o Kyoto Daigaku Igakubu Yakurigaku Kyoshitsu, Konoe-cho,
Yoshida, Sakyo-ku, Kyoto 606, Japan) V.40- 1944- Volume(issue)/page/year:
64,159,1968

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 275 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation)
Behavioral - convulsions or effect on seizure threshold
Gastrointestinal - changes in structure or function of salivary glands
REFERENCE :
NYKZAU Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. (Nippon
Yakuri Gakkai, c/o Kyoto Daigaku Igakubu Yakurigaku Kyoshitsu, Konoe-cho,
Yoshida, Sakyo-ku, Kyoto 606, Japan) V.40- 1944- Volume(issue)/page/year:
64,159,1968

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rabbit
DOSE/DURATION : 13 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and
D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,138,1972

** MUTATION DATA **

TYPE OF TEST : Cytogenetic analysis
ROUTE OF EXPOSURE : Unreported
TEST SYSTEM : Human
DOSE/DURATION : 229 ug/kg
REFERENCE :
HUMAA7 Humangenetik. (Heidelberg, Fed. Rep. Ger.) V.1-30, 1964-75. For
publisher information, see HUGEDQ. Volume(issue)/page/year: 9,281,1970

*** REVIEWS ***

TOXICOLOGY REVIEW
JMTHBU Journal of the Medical Association of Thailand. (Businesss Mgr.,
Dept. of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok 7,
Thailand) V.1- 1918- Volume(issue)/page/year: 58,623,1975

*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***

NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA :
NOES - National Occupational Exposure Survey (1983)
NOES Hazard Code - X7177
No. of Facilities: 25 (estimated)
No. of Industries: 1
No. of Occupations: 1
No. of Employees: 1358 (estimated)
No. of Female Employees: 956 (estimated)

*** STATUS IN U.S. ***

EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus


*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
Indolo(1,7-ab)(1)benzazepine-1-ethanamine,6,7-dihydro-N-methyl-N-(phenylmethyl)-,monohydrochloride 57529-83-6
Indolo(1,7-ab)(1)benzazepine-1-ethanamine,6,7-dihydro-N,N,2-trimethyl- 57529-86-9
Indolo(1,7-ab)(1)benzazepine-1-methanamine,6,7-dihydro-N,N-dimethyl- 57529-89-2
Indolo(1,7-ab)(1)benzazepine-2-methanamine,6,7-dihydro-N,N-dimethyl-, monohydrochloride 41987-47-7
Indolo(1,7-ab)(1)benzazepine-2-methanamine,6,7-dihydro-N,N-dimethyl-1-phenyl- 57529-92-7
Indolo(1,7-ab)(1)benzazepine-2-methanamine,6,7-dihydro-N,N,1-trimethyl- 57529-91-6
2-Indolinone,3-(2-(tert-butylamino)ethyl)-1-(dimethylamino)-3-phenyl-, monohydrochloride 40713-82-4
7H-Indolo(3,4-gh)(1,4)benzoxazine,4,6,6a,8,9,10a-hexahydro-5-bromo-7-methyl-, oxalate,(+-)-(6-ars,10-ars)- 84132-04-7
7H-Indolo(3,4-gh)(1,4)benzoxazine,4,6,6a,8,9,10a-hexahydro-7-methyl-,monohydrochloride, (+-)-, (6-ars,10-ars)- 77291-63-5
7H-Indolo(3,4-gh)(1,4)benzoxazine,4,6,6a,8,9,10a-hexahydro-, monohydrochloride, (+-)-,(6-ars,10-ars) 80952-17-6
7H-Indolo(3,4-gh)(1,4)benzoxazine,4,6,6a,8,9,10a-hexahydro-7-propyl-,monohydrochloride, (+-)-, (6-ars,10-ars)- 80952-18-7
7H-Indolo(3,4-gh)(1,4)benzoxazine,4,5,5a,6,6a,8,9,10a-octahydro-7-propyl-, (+-)-,(5a-RS(5a-alpha,6a-beta,10a-alpha))- 84132-03-6
Indolo(7,6-g)indole-3,8-dimethanaminium,1,6-dihydro-N,N,N,N',N',N'-hexamethyl-, bis(methylsulfate) 84132-03-6
Indol-5-ol 1953-54-4
1H-Indol-5-ol,2-(4-(acetyloxy)phenyl)-1-ethyl-3-methyl-, acetate(ester) 86111-26-4
Indol-5-ol, 3-(2-aminoethyl)- 50-67-9
Indol-5-ol, 3-(2-aminoethyl)-, acetate (ester),adipate (1:1) 19628-29-6
2-Indolinone,1-((p-chlorobenzyl)methylamino)-3-(2-(diethylamino)ethyl)-3-phenyl- 33391-15-0
Indol-5-ol, 3-(2-aminoethyl)-, adipate 16031-83-7
Indol-5-ol, 3-(2-aminoethyl)-, p-aminobenzoate(ester), dihydrochloride 19616-00-3
Indol-5-ol, 3-(2-aminoethyl)-, benzoate (ester),monoacetate 18518-64-4
Indol-5-ol, 3-(2-aminoethyl)-,(m-chlorophenyl)carbamate, hydrochloride 73816-59-8
Indol-5-ol, 3-(2-aminoethyl)-, compd. with creatininesulfate 971-74-4
Indol-5-ol, 3-(2-aminoethyl)-, compd. with creatininesulfate monohydrate, mixed with sodium nitrite 971-74-4
Indol-5-ol, 3-(2-aminoethyl)-, diethylcarbamate,acetate 73816-60-1
Indol-5-ol, 3-(2-aminoethyl)-, maleate 18525-25-2
Indol-5-ol, 3-(2-aminoethyl)-, methylcarbamate,hydrochloride 73816-61-2
1H-Indol-5-ol, 3-(2-aminoethyl)-, monohydrochloride,nitrosated 73816-61-2
2-Indolinone,1-((o-chlorobenzyl)methylamino)-3-(3-(diethylamino)propyl)-3-phenyl- 33456-35-8
Indol-5-ol, 3-(2-aminoethyl)-, phenylcarbamate,hydrochloride 73816-62-3
Indol-5-ol, 3-(2-aminoethyl)-, propionate (ester),adipate (1:1) 19628-28-5
Indol-5-ol, 3-(2-aminoethyl)-, succinate 21716-89-2
Indol-5-ol, 3-(2-aminoethyl)-, sulfate 2906-14-1
1H-Indol-5-ol, 3-(2-(4-amino-1-piperidinyl)ethyl)-,hydrochloride, hydrate (2:4:1) 35633-80-8
Indol-5-ol, 3-(2-aminopropyl)-, hydrochloride 101651-82-5
Indol-6-ol, 3-(2-aminopropyl)-5-methoxy-,hydrochloride 101651-83-6
Indol-3-ol,2-(((p-(bis(2-chloroethyl)amino)phenyl)imino)methyl)- 101651-84-7
3-Indolol,5-bromo-2-(9-chloro-3-hydroxynaphtho(1,2-b)thien-2-yl)-, bis(hydrogen sulfate), disodium salt 101651-84-7
Indol-6-ol,4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl- 83364-03-8
2-Indolinone,1-((p-chlorobenzyl)methylamino)-3-(2-(dimethylamino)ethyl)-3-phenyl- 33391-14-9
Indol-6-ol,4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-methyl- 83364-02-7
Indol-5-ol, 3-(2,3-diaminopropyl)-, dihydrochloride 101651-85-8
Indol-5-ol, 3-(2-(dibutylamino)ethyl)-,monohydrochloride 101651-85-8
1H-Indol-4-ol,4-(2-(3,4-dimethoxyphenyl)ethenyl)octahydro-,(3a-alpha,4-beta,4(Z),7a- alpha)-(+-)-,(Z)-2-butenedioate (2:1) (salt) 66690-81-1
Indol-4-ol, 3-(2-(dimethylamino)ethyl)- 520-53-6
Indol-5-ol, 3-(2-(dimethylamino)ethyl)- 487-93-4
Indol-6-ol, 3-(2-(dimethylamino)ethyl)- 1476-33-1
1H-Indol-5-ol, 3-(2-(dimethylamino)ethyl)-, bioxalate 4382-50-7
Indol-4-ol, 3-(2-(dimethylamino)ethyl)-, dihydrogenphosphate 520-52-5
Indol-5-ol, 3-(2-(dimethylamino)ethyl)-, oxalate 2963-79-3

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net